| Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M KS Thress, CP Paweletz, E Felip, BC Cho, D Stetson, B Dougherty, Z Lai, ... Nature medicine 21 (6), 560-562, 2015 | 1614 | 2015 |
| Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA MC Liu, GR Oxnard, EA Klein, C Swanton, MV Seiden, MC Liu, ... Annals of Oncology 31 (6), 745-759, 2020 | 1182 | 2020 |
| Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review JD Merker, GR Oxnard, C Compton, M Diehn, P Hurley, AJ Lazar, ... Archives of pathology & laboratory medicine 142 (10), 1242-1253, 2018 | 1043 | 2018 |
| Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non–small-cell lung cancer GR Oxnard, KS Thress, RS Alden, R Lawrance, CP Paweletz, M Cantarini, ... Journal of clinical oncology 34 (28), 3375-3382, 2016 | 923 | 2016 |
| Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA GR Oxnard, CP Paweletz, Y Kuang, SL Mach, A O'Connell, MM Messineo, ... Clinical cancer research 20 (6), 1698-1705, 2014 | 877 | 2014 |
| Rociletinib in EGFR-mutated non–small-cell lung cancer LV Sequist, JC Soria, JW Goldman, HA Wakelee, SM Gadgeel, A Varga, ... New England Journal of Medicine 372 (18), 1700-1709, 2015 | 847 | 2015 |
| Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020 | 801 | 2020 |
| MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met … MM Awad, GR Oxnard, DM Jackman, DO Savukoski, D Hall, P Shivdasani, ... Journal of clinical oncology 34 (7), 721-730, 2016 | 739 | 2016 |
| Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation GR Oxnard, ME Arcila, CS Sima, GJ Riely, J Chmielecki, MG Kris, W Pao, ... Clinical cancer research 17 (6), 1616-1622, 2011 | 730 | 2011 |
| Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay ME Arcila, GR Oxnard, K Nafa, GJ Riely, SB Solomon, MF Zakowski, ... Clinical cancer research 17 (5), 1169-1180, 2011 | 697 | 2011 |
| Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to osimertinib GR Oxnard, Y Hu, KF Mileham, H Husain, DB Costa, P Tracy, N Feeney, ... JAMA oncology 4 (11), 1527-1534, 2018 | 689 | 2018 |
| Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer AG Sacher, C Paweletz, SE Dahlberg, RS Alden, A O’Connell, N Feeney, ... JAMA oncology 2 (8), 1014-1022, 2016 | 616 | 2016 |
| Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer H Yasuda, E Park, CH Yun, NJ Sng, AR Lucena-Araujo, WL Yeo, ... Science translational medicine 5 (216), 216ra177-216ra177, 2013 | 601 | 2013 |
| Optimization of dosing for EGFR-mutant non–small cell lung cancer with evolutionary cancer modeling J Chmielecki, J Foo, GR Oxnard, K Hutchinson, K Ohashi, R Somwar, ... Science translational medicine 3 (90), 90ra59-90ra59, 2011 | 598 | 2011 |
| Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for … JE Chaft, GR Oxnard, CS Sima, MG Kris, VA Miller, GJ Riely Clinical cancer research 17 (19), 6298-6303, 2011 | 475 | 2011 |
| Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRA S and Presence of PIK3CA/AKT1 Mutations N Rekhtman, PK Paik, ME Arcila, LJ Tafe, GR Oxnard, AL Moreira, ... Clinical cancer research 18 (4), 1167-1176, 2012 | 458 | 2012 |
| New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer GR Oxnard, ME Arcila, J Chmielecki, M Ladanyi, VA Miller, W Pao Clinical cancer research 17 (17), 5530-5537, 2011 | 431 | 2011 |
| False-positive plasma genotyping due to clonal hematopoiesis Y Hu, BC Ulrich, J Supplee, Y Kuang, PH Lizotte, NB Feeney, NM Guibert, ... Clinical Cancer Research 24 (18), 4437-4443, 2018 | 426 | 2018 |
| Institutional implementation of clinical tumor profiling on an unselected cancer population LM Sholl, K Do, P Shivdasani, E Cerami, AM Dubuc, FC Kuo, EP Garcia, ... JCI insight 1 (19), e87062, 2016 | 404 | 2016 |
| Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim … LV Sequist, JY Han, MJ Ahn, BC Cho, H Yu, SW Kim, JCH Yang, JS Lee, ... The Lancet Oncology 21 (3), 373-386, 2020 | 396 | 2020 |